Brexanolone by Sage Therapeutics for Alcohol Dependence: Likelihood of Approval

Brexanolone is under clinical development by Sage Therapeutics and currently in Phase I for Alcohol Dependence.

Merck drug for rare, deadly lung condition appears set for approval in U.S.

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available

March 26, 2024

Opinion | Berry Eaters Beware: Hepatitis A May Be Lurking

Panosian Dunavan is an infectious diseases expert. *Patient’s name has been changed. Late last year, the U.S. began to see a tiny flurry of hepatitis

June 29, 2023

BICO company Biosero has signed an agreement to develop laboratory automation solutions to a value of 28 MUSD

Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for

December 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.